High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
146.89M
-0.42%
0.132
+64.59%
148.93M
+3.84%
0.157
+213.34%
155.09M
+7.75%
0.217
+14.04%
Estimates Revision
The market is revising Downward the revenue expectations for Azenta, Inc. (AZTA) for FY2026, with the revenue forecasts being adjusted by -0.14% over the past three months. During the same period, the stock price has changed by 15.84%.
Revenue Estimates for FY2026
Revise Downward
-0.14%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
-2.47%
In Past 3 Month
Stock Price
Go Up
+15.84%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast AZTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZTA is 37.33 USD with a low forecast of 31.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 35.100
Low
31.00
Averages
37.33
High
45.00
Current: 35.100
Low
31.00
Averages
37.33
High
45.00
Raymond James
Andrew Cooper
Outperform
maintain
$35 -> $45
2025-11-25
Reason
Raymond James
Andrew Cooper
Price Target
$35 -> $45
2025-11-25
maintain
Outperform
Reason
Raymond James analyst Andrew Cooper raised the firm's price target on Azenta to $45 from $35 and keeps an Outperform rating on the shares following a fiscal Q4 report that the firm describes as "generally in line to above hopes." An investor day in just a few weeks should "shed major light on the longer-term view," says the analyst, who thinks it will be in the mid-single-digit-plus organic revenue range with a path to margins breaching 20%, leaving the firm "optimistic on the trajectory."
Nephron Research
Thomas DeBourcy
Sell -> Hold
upgrade
$31
2025-11-24
Reason
Nephron Research
Thomas DeBourcy
Price Target
$31
2025-11-24
upgrade
Sell -> Hold
Reason
Nephron Research analyst Thomas DeBourcy upgraded Azenta to Hold from Sell with a $31 price target.
Jefferies
Hold
to
Buy
upgrade
$30 -> $38
2025-10-30
Reason
Jefferies
Price Target
$30 -> $38
2025-10-30
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Azenta to Buy from Hold with a price target of $38, up from $30. The firm sees an attractive setup for the shares into 2026. The company has "healthy" biopharma exposure and "plenty of growth drivers" from innovation, pricing, attach rates and potential acquisitions, the analyst tells investors in a research note. Jefferies believes the shares can re-rate higher as investors gain confidence in Azenta's mid-term opportunity.
Raymond James
Market Perform
to
Outperform
upgrade
$35
2025-08-06
Reason
Raymond James
Price Target
$35
2025-08-06
upgrade
Market Perform
to
Outperform
Reason
Raymond James upgraded Azenta to Outperform from Market Perform with a $35 price target. While the Q3 print was "noisy," it drove the stock to a level that the firm believes will be a bottom, the analyst tells investors in a research note. Raymond James views the Q3 results as a clearing event and is hopeful that "reasonable" performance going forward, especially if/when the end market improves, supports a return to more reasonable multiples.
Evercore ISI
Vijay Kumar
In Line
downgrade
$35 -> $33
2025-08-05
Reason
Evercore ISI
Vijay Kumar
Price Target
$35 -> $33
2025-08-05
downgrade
In Line
Reason
Evercore ISI analyst Vijay Kumar lowered the firm's price target on Azenta to $33 from $35 and keeps an In Line rating on the shares. Macro uncertainty that led to order pushouts and Q4 guidance are weighing on the stock, says the analyst, who adds that the Street is "questioning the 4Q visibility" given macro uncertainty.
Stephens
Stephens
initiated
$35
2025-07-21
Reason
Stephens
Stephens
Price Target
$35
2025-07-21
initiated
Reason
Stephens resumed coverage of Azenta with an Equal Weight rating and $35 price target. While "encouraged" by the new management team's efforts to streamline the portfolio and believing that there is "a lot of room for improvement on the margin side," the firm prefers to take more of a "wait-and-see approach" until the macro overhang improves, the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Azenta Inc (AZTA.O) is 44.52, compared to its 5-year average forward P/E of 189.27. For a more detailed relative valuation and DCF analysis to assess Azenta Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
189.27
Current PE
44.52
Overvalued PE
489.82
Undervalued PE
-111.28
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
35.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
62.32
Undervalued EV/EBITDA
9.58
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.52
Current PS
0.00
Overvalued PS
8.55
Undervalued PS
2.49
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AZTA News & Events
Events Timeline
(ET)
2025-11-21
06:51:25
Azenta projects 3%-5% growth in organic revenue for FY26
2025-11-21
06:50:24
Azenta updates its previously released financial reports.
2025-11-21
06:48:25
Azenta announces Q4 earnings per share of 21 cents, surpassing consensus estimate of 20 cents.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/215b2a63374156f0486412fd7d8a1bcada98b3b0491401bac7835ad3b1088809.jpg)
Preview
4.5
11-22NASDAQ.COMStocks Surge as Semiconductor Companies Recover
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/8948da3dc282ea167e53c1bf6201d8ccebc0fae015d90e0e61235bf51bd26764.jpg)
Preview
4.5
11-22NASDAQ.COMStocks Continue Upward Trend Following Dovish Comments from Williams
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/3a32cbb9e1ddf9ebc44c09ebc953efdfe55cdad4e52e26a3a69c39e271609390.png)
Preview
2.0
11-22CNBCMidday Stock Highlights: Notable Movements from Oracle, Bath & Body Works, Gap, and Others
Sign Up For More News
People Also Watch
FAQ
What is Azenta Inc (AZTA) stock price today?
What is Azenta Inc (AZTA)'s business?
What is the price predicton of AZTA Stock?
What is Azenta Inc (AZTA)'s revenue for the last quarter?
What is Azenta Inc (AZTA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Azenta Inc (AZTA)'s fundamentals?
How many employees does Azenta Inc (AZTA). have?